D
Duoning Biotech
Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts
About Duoning Biotech
Duoning Bio is a leading provider of bioprocess solutions tailored for the biopharmaceutical industry. The company specializes in offering a comprehensive range of products and services that enhance production efficiency and ensure high product quality. Duoning Bio serves clients in the biopharmaceutical sector, including manufacturers of vaccines, monoclonal antibodies, and other biologics. Operating primarily in the bioprocessing market, the company leverages its expertise to deliver customized solutions that meet the stringent regulatory requirements of the industry.
The business model of Duoning Bio revolves around the sale of bioprocessing equipment, consumables, and technical services. Revenue is generated through direct sales of these products and services, as well as through long-term service contracts with biopharmaceutical companies. The company’s offerings include single-use systems, cell culture media, and downstream processing solutions, all designed to streamline the biomanufacturing process.
Duoning Bio differentiates itself through its commitment to innovation and quality, continually investing in research and development to stay ahead of industry trends. The company’s technical services team provides expert support to clients, ensuring optimal performance of their bioprocessing operations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Huangpu, China
- Employees
- 24
- Open positions
- 1
- Dealroom signal
- 45.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Investment activity
- 1 company, latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES CEquity / VC | Nov 2021 | $0 | — | Sequoia · 99Fund · Lake Bleu Capital | — |
| SERIES A✓Equity / VC | Apr 2019 | $15M | $60M | Ally Bridge Group | — |
Growth signals
Latest recorded traffic for Duoning Biotech is 7K monthly website visits, up 250% over the last three months. Duoning Biotech's team grew 4.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Ally Bridge Group
Series B and later3 investors entered at this stage
Sequoia
99Fund
Lake Bleu Capital
Other known investors1 additional known investor
HSG
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Duoning Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Duoning Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.